Related Experiment Video
Updated: May 17, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety
Imtiaz Salim1, Jassim Al Suwaidi, Wissam Ghadban
1Hamad Medical Corp., Doha, Qatar.
Insights
Patients with atrial fibrillation (AF) and chronic kidney disease (CKD) face increased stroke risk. Warfarin anticoagulation is key for stroke prevention in CKD patients, but newer agents need further study.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Patients with atrial fibrillation (AF) and chronic kidney disease (CKD) have a higher stroke incidence.
- AF prevalence has increased in CKD patients over the past two decades.
- Warfarin's safety and efficacy in severe CKD for AF stroke prevention remain under-documented.
Purpose of the Study:
- To review the risks and benefits of long-term anticoagulation in AF patients with CKD.
- To explore the role of novel anticoagulant agents in this patient population.
Main Methods:
- A Medline literature search was conducted from 1980 to 2012.
- Keywords included 'chronic kidney disease,' 'atrial fibrillation,' 'hemodialysis,' 'warfarin,' 'anticoagulation,' and 'new oral anticoagulants.'
Main Results:
- Long-term warfarin anticoagulation with monitoring is considered essential for stroke prevention in CKD patients.
- Evidence on newer agents in this population is limited.
Conclusions:
- Warfarin is the current cornerstone for stroke prevention in CKD patients with AF.
- Further research is needed to evaluate newer anticoagulants for safety and efficacy in this high-risk group to reduce stroke incidence.
Introduction:
Patients with atrial fibrillation (AF) and chronic kidney disease (CKD) are individually associated with a higher incidence of stroke as compared with the general population. Over the last two decades, an increase in prevalence of AF is seen in patients with CKD. While long-term anticoagulation with warfarin is well established to reduce the risk of thromboembolic event in patients with AF, its safety and efficacy has not been documented in patients with severe CKD.
Areas Covered:
In this review, the authors analyze the risk and benefit of long term anticoagulation across the spectrum of AF patients with CKD and explore the role of novel agents in this unique patient population. A Medline search of the English literature published between 1980 and 2012 was performed using the heading 'chronic kidney disease' combined with 'atrial fibrillation', 'hemodialysis', 'warfarin', 'anticoagulation' and 'new oral anticoagulants'.
Expert Opinion:
Long-term anticoagulation with warfarin under strict monitoring appears to be the cornerstone of therapy in patients with CKD to prevent stroke. Further research is warranted to explore the safety and efficacy of newer anticoagulant agents in these high-risk patients in order to reduce the incidence of disabling stroke.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease III: Interprofessional Care
Cardiac Catheterization I: Pre-Procedure Overview
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Acute Kidney Injury V: Interprofessional Care
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
